Antiretroviral-based HIV prevention strategies for women

References

• Elias C, Coggins C. Female-controlled methods to prevent sexual transmission of HIV. AIDS10, S43–S51 (1996).
   PubMed Web of Science ®Google Scholar
• Susser I, Stein Z. Culture, sexuality, and women’s agency in the prevention of HIV/AIDS in southern Africa. Am. J. Public Health90, 1042–1048 (2000).
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitusittithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med.361, 2209–2220 (2009).
   PubMed Web of Science ®Google Scholar
• Cohen J. Is an effective HIV vaccine feasible? Science309(5731), 99 (2005).
   PubMed Web of Science ®Google Scholar
• Bailey RC, Moses S, Parker CB et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomized controlled trial. Lancet369, 643–676 (2007).
   PubMed Web of Science ®Google Scholar
• Auvert B. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the NNRS 1265 trial. PLoS Med.2(11), e298 (2005).
   PubMed Web of Science ®Google Scholar
• Gray RH, Kigoz G, Serwadda D et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomized trial. Lancet369, 657–666 (2007).
   PubMed Web of Science ®Google Scholar
• Van Damme L, Ramjee G, Alary M, Vuylsteke B. Effectiveness of Col-1492, a nonoxynol-9 vaginal gel, on HIV transmisison in female sex workers: a randomized controlled trial. Lancet360, 917–927 (2002).
   Google Scholar
• Hillier S, Moench T, Shattock R et al.In vitro and in vivo: the story of nonoxynol 9. J. Acquir. Immune Defic. Syndr.39, 1–8 (2005).
   PubMed Web of Science ®Google Scholar
• Van Damme L, Govinden R, Mirembe FM et al. Lack of effectiveness of cellulose sulphate gel for prevention of vagina HIV transmission N. Engl. J. Med.359, 463–472 (2008).
   PubMed Web of Science ®Google Scholar
• Karim SA, Richardson B, Ramjee G et al. Safety and effectiveness of buffer gel and 0.5% Pro 2000 gel for prevention of HIV infection in women: results of HPTN 035 microbicide trial. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montréal, Canada, February 8–11 2009.
   Google Scholar
• McCormack S, Ramjee G, Kamila A et al. PRO200 vaginal gel for HIV prevention: results of the MDP301 Phase III randomized microbial trial. Lancet (2010) (In press).
   PubMedGoogle Scholar
• Van Rompay KK, Marthas ML, Ramos RA et al. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3’-azido-3’-deoxythymidine prevents SIV infection. Antimicrob. Agents Chemother.36, 2381–2386 (1992).
   PubMedGoogle Scholar
• Tsai C, Follis KE, Sabo A et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science270, 1197–1199 (1995).
   PubMed Web of Science ®Google Scholar
• Subbarao S, Otten RA, Ramos A et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J. Infect. Dis.194, 904–911 (2006).
   PubMed Web of Science ®Google Scholar
• Cranage M, Sharpe S, Herrera C et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med.5, e157 (2008).
   PubMed Web of Science ®Google Scholar
• Parikh UM, Dobard C, Sharma S et al. Complete protection from repeated vaginal simian–human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J. Virol.83, 10358–10365 (2009).
   PubMed Web of Science ®Google Scholar
• Chenine AL, Siddappa NB, Kramer VG et al. Relative transmissibility of an R5 clade C simian–human immunodeficiency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes. J. Infect. Dis.201, 1155–1163 (2010).
   PubMedGoogle Scholar
• Tsai C, Emau P, Follis KE et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl)adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J. Virol.72, 4265–4273 (1998).
   PubMed Web of Science ®Google Scholar
• Kubo M, Nishimura Y, Shingai M et al. Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease. J. Virol.83, 7099–7108 (2009).
   PubMedGoogle Scholar
• Garcia-Lerma JG, Otten RA, Qari SH et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med.5, e28 (2008).
   PubMed Web of Science ®Google Scholar
• Garcia-Lerma J, Cong M, Mitchell J et al. Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. Sci. Transl. Med.2, 14ra14 (2010).
   PubMedGoogle Scholar
• Denton PW, Estes JD, Sun Z et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med.5, e16 (2008).
   PubMed Web of Science ®Google Scholar
• García-Lerma JG, Paxton L, Kilmarx PH, Heneine W. Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol. Sci.31, 74–81 (2010).
   PubMed Web of Science ®Google Scholar
• Pereira AS, Kashuba AD, Fiscus SA et al. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J. Infect. Dis.180, 2039–2043 (1999).
   PubMed Web of Science ®Google Scholar
• Min SS CA, Rezk N, Cu-Uvin S et al. Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J. Acquir. Immune Defic. Syndr.37(5), 1577–1580 (2004).
   PubMed Web of Science ®Google Scholar
• Dumond JB, Yeh RF, Patterson KB et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS21, 1899–1907 (2007).
   PubMed Web of Science ®Google Scholar
• Vourvahis M, Tappouni HL, Patterson KB et al. The pharmacokinetics and viral activity of tenofovir in the male genital tract. J. Acquir. Immune Defic. Syndr.47, 329–333 (2008).
   PubMedGoogle Scholar
• Peterson L, Taylor D, Roddy R, Belai G, Phillips P. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a Phase 2, double blind, randomized, placebo controlled trial. PLoS Clin. Trials2(5), e27 (2007).
   PubMedGoogle Scholar
• Karim QA, Karim SA, Frolich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science329(5996), 1168–1174 (2010).
   PubMed Web of Science ®Google Scholar
• Smith DK, Grohskopf LA, Black RJ et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm. Rep.54(RR02), 1–20 (2005).
   PubMedGoogle Scholar
• Landovitz RJ, Currier JS. Clinical practice. Postexposure prophylaxis for HIV infection. N. Engl. J. Med.361, 1768–1777 (2009).
   PubMed Web of Science ®Google Scholar
• Jones A, Talameh J, Patterson K et al. First-dose and steady-state pharmacokinetics (PK) of raltegravir (RAL) in the genital tract (GT) of HIV uninfected women. Presented at: 10th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, The Netherlands, 15–17 April 2009.
   Google Scholar
• Mayer K, Mimiaga M, Gelman M et al. Tenofovir DF/emtricitabine/raltegravir (TDF/FTC/RAL) appears safe and well-tolerated for non-occupational post-exposure prophylaxis (NPEP). Presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, 19–22 July 2009.
   Google Scholar
• Granich R, Gilks C, Dye C, De Cock K, Williams B. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet373, 48–57 (2009).
   PubMed Web of Science ®Google Scholar
• Granich R, Crowley S, Vitoria M et al. Highly active antiretroviral treatment for the prevention of HIV transmission. J. Int. AIDS Soc.13, 1 (2010).
   PubMed Web of Science ®Google Scholar
• Siegfried N, Uthman OA, Rutherford GW. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. Cochrane Database Syst. Rev.3, CD008272 (2010).
   PubMed Web of Science ®Google Scholar
• Auvert B, Males S, Puren A et al. Can highly active antiretroviral therapy reduce the spread of HIV? A study in a township of South Africa. J. Acquir. Immune Defic. Syndr.36, 613–621 (2004).
   PubMed Web of Science ®Google Scholar
• Das-Douglas M, Chu P, Santos G-M et al. Decreases in community viral load are associated with a reduction in new HIV diagnoses in San Francisco. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16–19 February 2010 (Abstract 33).
   Google Scholar
• Kalichman S, Eaton L, Cherry C. Sexually transmitted infectious and infectiousness beliefs among people living with HIV/AIDS: implications for HIV treatment as prevention. HIV Med.11(8), 502–509 (2010).
   PubMed Web of Science ®Google Scholar
• Taber R, Rajakumar PA, Fuller DH et al. Effects of monotherapy with (R)-9-(2-phonsphonylmethoxypropyl)adenine (PMPA) on the evolution of a primary Simian immunodeficiency virus (SIV) isolate. Virology354, 116–131 (2006).
   PubMedGoogle Scholar
• Van Rompay KKA, Johnson JA, Blackwood EJ et al. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology4, 25 (2007).
   PubMedGoogle Scholar
• Miller C, Shattock R. Target cells in vaginal HIV transmission. Microbes Infect.5, 59–67 (2003).
   PubMed Web of Science ®Google Scholar
• Fleming TR, Richardson BA. Some design issues in trials of microbicides for prevention of HIV infection J. Infect. Dis.190, 666–674 (2004).
   PubMed Web of Science ®Google Scholar
• Basic design features: size, duration and type of trials and choice of control group. In: Methodological Challenges in Biological HIV Prevention Trials. Lagakos SW, Gable AR (Eds). Institute of Medicine of the National Academies, The National Academic Press, Washington, DC, USA, 69–87 (2008).
   Google Scholar
• Roddy RE, Zekeng L, Ryan KA, Tamoufé U, Weir SS, Wong EL. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N. Engl. J. Med.339(8), 504–510 (1998).
   PubMed Web of Science ®Google Scholar
• Feldblum PJ, Adeiga A, Bakare R et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One3(1), e1474 (2008).
   PubMed Web of Science ®Google Scholar
• Halpern V, Ogunsola F, Obunge O et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS ONE3(11), e3784 (2008).
   PubMed Web of Science ®Google Scholar
• Skoler-Karpoff S, Ramjee G, Ahmed K et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet372(9654), 1977–1987 (2008).
   PubMed Web of Science ®Google Scholar